ClinicalTrials.gg
CompletedNCT01659255Updated Mar 16, 2021Results posted

Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL

A Phase 1 interventional study of Tirabrutinib in Non Hodgkins Lymphoma and Chronic Lymphocytic Leukaemia, sponsored by Gilead Sciences. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-16.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Lymphoma, Non-Hodgkin by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Lymphoma, Non-Hodgkin · Gilead Sciences.

Enrollment
6th of 20
90 · median 39
Started
2012
with 2 others
Phase 1
6 of 21
none open now
Registered
16th of 21
by date

Among the 21 studies in Lymphoma, Non-Hodgkin by Gilead Sciences, this one is the 6th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2012, is one of 6 in phase 1, and was the 16th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

None of the 21 studies in Lymphoma, Non-Hodgkin by Gilead Sciences is open now. The open studies under Lymphoma, Non-Hodgkin, anywhere →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Lymphoma, Non-Hodgkin by Gilead Sciences as a file.
02

Study summary

The primary objective of the study is to evaluate the safety and tolerability of tirabrutinib (formerly ONO/GS-4059) given as monotherapy to participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

03

Conditions studied

  • Non Hodgkins Lymphoma
  • Chronic Lymphocytic Leukaemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Males or females with a confirmed diagnosis of and documented history of malignant disease (B-cell lymphoma and/or CLL) for which no therapy of curative or high priority exists and for whom treatment with a Btk inhibitor may be deemed appropriate.
  2. Age ≥ 18 years.
  3. (ECOG) performance status of ≤ 2.

Key Exclusion Criteria:

  1. Central nervous system (CNS) lymphoma.
  2. Women who are pregnant or lactating.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Tirabrutinib 20 mg Once Daily (CLL)

    Participants with relapsed/refractory chronic lymphocytic leukaemia (CLL) received tirabrutinib 20 mg once daily.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 40 mg Once Daily (CLL)

    Participants with relapsed/refractory CLL received tirabrutinib 40 mg once daily.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 80 mg Once Daily (CLL)

    Participants with relapsed/refractory CLL received tirabrutinib 80 mg once daily.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 160 mg Once Daily (CLL)

    Participants with relapsed/refractory CLL received tirabrutinib 160 mg once daily.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 320 mg Once Daily (CLL)

    Participants with relapsed/refractory CLL received tirabrutinib 320 mg once daily.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 400 mg Once Daily (CLL)

    Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 500 mg Once Daily (CLL)

    Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 600 mg Once Daily (CLL)

    Participants with relapsed/refractory CLL received tirabrutinib 600 mg once daily.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 300 mg Twice Daily (CLL)

    Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 20 mg Once Daily (NHL)

    Participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) received tirabrutinib 20 mg once daily.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 40 mg Once Daily (NHL)

    Participants with relapsed/refractory NHL received tirabrutinib 40 mg once daily.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 80 mg Once Daily (NHL)

    Participants with relapsed/refractory NHL received tirabrutinib 80 mg once daily.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 160 mg Once Daily (NHL)

    Participants with relapsed/refractory NHL received tirabrutinib 160 mg once daily.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 320 mg Once Daily (NHL)

    Participants with relapsed/refractory NHL received tirabrutinib 320 mg once daily.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 480 mg Once Daily (NHL)

    Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 600 mg Once Daily (NHL)

    Participants with relapsed/refractory NHL received tirabrutinib 600 mg once daily.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib 240 mg Twice Daily (NHL)

    Participants with relapsed/refractory NHL received tirabrutinib 240 mg twice daily.

    Drug: Tirabrutinib

Interventions

  • Capsules administered orally

    Also known as: ONO/GS-4059

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Dose-Limiting Toxicities

    Dose Limiting Toxicities (DLT) were defined as follows: * All Common Terminology Criteria (CTC) Grade 4 tirabrutinib related adverse events * All CTC Grade 3 tirabrutinib related adverse events, with the exception of the following: * CTC Grade 3 lymphocytosis considered an expected outcome of therapy Any toxicity which in the opinion of the Investigator is attributed to a participant's underlying disease was not considered a DLT.

    Time frame: Day 1 through Day 28

Secondary outcomes

  1. Overall Response Rate

    Overall response rate (ORR) was defined as the percentage of participants who achieve a best overall response of complete remission (CR, unconfirmed complete response (CRu), complete response with incomplete marrow recovery (CRi)) or partial remission (PR, nodal PR) during study as assessed by the investigator. ORR assessment was defined per following standardized criteria: * NHL: Cheson, 1999 * CLL: International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008

    Time frame: Up to Cycle 37 (28 days for each cycle) plus 6-month intervals thereafter until disease progression (maximum: up to 39 months)

  2. Pharmacokinetic (PK) Parameter: Cmax of Tirabrutinib

    Cmax is defined as the maximum concentration of drug.

    Time frame: Pre-dose, then 30 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose at Cycle 1, Day 28

  3. PK Parameter: AUCtau of Tirabrutinib

    AUCtau is defined as concentration of drug over dosing interval.

    Time frame: Pre-dose, then 30 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose at Cycle 1, Day 28

07

Results

Posted Jan 28, 2021

Participant flow

Participants were enrolled at study sites in Europe. The first participant was screened on 17 August 2012. The last study visit occurred on 11 January 2016.

Participant flow — Overall Study
MilestoneTirabrutinib 20 mg Once Daily (CLL)Tirabrutinib 40 mg Once Daily (CLL)Tirabrutinib 80 mg Once Daily (CLL)Tirabrutinib 160 mg Once Daily (CLL)Tirabrutinib 320 mg Once Daily (CLL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL)Tirabrutinib 300 mg Twice Daily (CLL)Tirabrutinib 20 mg Once Daily (NHL)Tirabrutinib 40 mg Once Daily (NHL)Tirabrutinib 80 mg Once Daily (NHL)Tirabrutinib 160 mg Once Daily (NHL)Tirabrutinib 320 mg Once Daily (NHL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 600 mg Once Daily (NHL)Tirabrutinib 240 mg Twice Daily (NHL)
Started3343333333358211093
Completed12433211200103240
Not completed210001221334818853
Withdrew: Adverse event00000110010102010
Withdrew: Death01000001100011210
Withdrew: Progressive disease200000010223513623
Withdrew: Withdrew consent00000000001001000
Withdrew: Investigator decision00000000000011000
Withdrew: Sponsor's decision00000010000000000
Withdrew: Completed treatment per protocol at the time00000000000000010
Withdrew: Participant went on to have an allograft00000000000010000

Outcome measures

PrimaryPercentage of Participants Experiencing Dose-Limiting Toxicities

Dose Limiting Toxicities (DLT) were defined as follows: * All Common Terminology Criteria (CTC) Grade 4 tirabrutinib related adverse events * All CTC Grade 3 tirabrutinib related adverse events, with the exception of the following: * CTC Grade 3 lymphocytosis considered an expected outcome of therapy Any toxicity which in the opinion of the Investigator is attributed to a participant's underlying disease was not considered a DLT.

Time frame:
Day 1 through Day 28
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Dose-Limiting Toxicities
percentage of participantsTirabrutinib 20 mg Once Daily (CLL)Tirabrutinib 40 mg Once Daily (CLL)Tirabrutinib 80 mg Once Daily (CLL)Tirabrutinib 160 mg Once Daily (CLL)Tirabrutinib 320 mg Once Daily (CLL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL)Tirabrutinib 300 mg Twice Daily (CLL)Tirabrutinib 20 mg Once Daily (NHL)Tirabrutinib 40 mg Once Daily (NHL)Tirabrutinib 80 mg Once Daily (NHL)Tirabrutinib 160 mg Once Daily (NHL)Tirabrutinib 320 mg Once Daily (NHL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 600 mg Once Daily (NHL)Tirabrutinib 240 mg Twice Daily (NHL)
Percentage of Participants Experiencing Dose-Limiting Toxicities0.00.00.00.00.033.30.00.033.30.00.00.00.04.810.022.20.0
SecondaryOverall Response Rate

Overall response rate (ORR) was defined as the percentage of participants who achieve a best overall response of complete remission (CR, unconfirmed complete response (CRu), complete response with incomplete marrow recovery (CRi)) or partial remission (PR, nodal PR) during study as assessed by the investigator. ORR assessment was defined per following standardized criteria: * NHL: Cheson, 1999 * CLL: International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008

Time frame:
Up to Cycle 37 (28 days for each cycle) plus 6-month intervals thereafter until disease progression (maximum: up to 39 months)
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsChronic Lymphocytic LeukaemiaNHL Subtype FLNHL Subtype SLLNHL Subtype WMNHL Subtype MZLNHL Subtype DLBCLNHL Subtype MCL
Overall Response Rate85.70.00.033.350.031.468.8
SecondaryPharmacokinetic (PK) Parameter: Cmax of Tirabrutinib

Cmax is defined as the maximum concentration of drug.

Time frame:
Pre-dose, then 30 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose at Cycle 1, Day 28
Reported as:
Mean · ng/mL
Pharmacokinetic (PK) Parameter: Cmax of Tirabrutinib
ng/mLTirabrutinib 20 mg Once Daily (CLL or NHL)Tirabrutinib 40 mg Once Daily (CLL or NHL)Tirabrutinib 80 mg Once Daily (CLL or NHL)Tirabrutinib 160 mg Once Daily (CLL or NHL)Tirabrutinib 320 mg Once Daily (CLL or NHL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL or NHL)Tirabrutinib 240 mg Twice Daily (NHL)Tirabrutinib 300 mg Twice Daily (CLL)
Pharmacokinetic (PK) Parameter: Cmax of Tirabrutinib73.4 ± 18.26164.5 ± 47.22241 ± 90.68539.6 ± 141.581181.6 ± 380.39826.5 ± 499.921240.3 ± 516.991230 ± 285.831265.2 ± 486.21704.3 ± 254.51674.3 ± 93.78
SecondaryPK Parameter: AUCtau of Tirabrutinib

AUCtau is defined as concentration of drug over dosing interval.

Time frame:
Pre-dose, then 30 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose at Cycle 1, Day 28
Reported as:
Mean · h*ng/mL
PK Parameter: AUCtau of Tirabrutinib
h*ng/mLTirabrutinib 20 mg Once Daily (CLL or NHL)Tirabrutinib 40 mg Once Daily (CLL or NHL)Tirabrutinib 80 mg Once Daily (CLL or NHL)Tirabrutinib 160 mg Once Daily (CLL or NHL)Tirabrutinib 320 mg Once Daily (CLL or NHL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL or NHL)Tirabrutinib 240 mg Twice Daily (NHL)Tirabrutinib 300 mg Twice Daily (CLL)
PK Parameter: AUCtau of Tirabrutinib306.4 ± 74.92660.1 ± 310.95762 ± 374.942681.8 ± 1055.175664.8 ± 1829.075259.5 ± 3166.577999.8 ± 2006.196766.9 ± 1025.648442.2 ± 2499.223415.5 ± 1296.473297.2 ± 1330

Adverse events

Collected over Adverse Events: First dose date up to the last dose date plus 30 days (maximum: 36 months); All-Cause Mortality: First dose date up to 39 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Chronic Lymphocytic Leukaemia5/28 (17.9%)17/28 (60.7%)28/28 (100%)
Non-Hodgkin's Lymphoma38/62 (61.3%)23/62 (37.1%)55/62 (88.7%)
Most frequent serious events
Showing 10 of 66
Most frequent serious events
EventChronic Lymphocytic LeukaemiaNon-Hodgkin's Lymphoma
Lower respiratory tract infectionInfections and infestations4/283/62
PyrexiaGeneral disorders3/281/62
Febrile neutropeniaBlood and lymphatic system disorders2/281/62
Neutropenic sepsisInfections and infestations2/280/62
Lymphocytic infiltrationBlood and lymphatic system disorders1/280/62
NeutropeniaBlood and lymphatic system disorders1/280/62
Spontaneous haematomaBlood and lymphatic system disorders1/280/62
Inguinal hernia strangulatedGastrointestinal disorders1/280/62
Abdominal abscessInfections and infestations1/280/62
BacteraemiaInfections and infestations1/280/62
Most frequent other events
Showing 10 of 96
Most frequent other events
EventChronic Lymphocytic LeukaemiaNon-Hodgkin's Lymphoma
AnaemiaBlood and lymphatic system disorders9/2823/62
ContusionInjury, poisoning and procedural complications10/288/62
NeutropeniaBlood and lymphatic system disorders9/289/62
NasopharyngitisInfections and infestations9/2811/62
ThrombocytopeniaBlood and lymphatic system disorders4/2818/62
DiarrhoeaGastrointestinal disorders6/2818/62
FallInjury, poisoning and procedural complications8/285/62
ArthralgiaMusculoskeletal and connective tissue disorders8/285/62
CoughRespiratory, thoracic and mediastinal disorders8/289/62
PyrexiaGeneral disorders7/287/62

Baseline characteristics

The Full Analysis Set included all the participants who received at least 1 dose of study drug.

Age, Customized
Age, Customized(Participants)Tirabrutinib 20 mg Once Daily (CLL)Tirabrutinib 40 mg Once Daily (CLL)Tirabrutinib 80 mg Once Daily (CLL)Tirabrutinib 160 mg Once Daily (CLL)Tirabrutinib 320 mg Once Daily (CLL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL)Tirabrutinib 300 mg Twice Daily (CLL)Tirabrutinib 20 mg Once Daily (NHL)Tirabrutinib 40 mg Once Daily (NHL)Tirabrutinib 80 mg Once Daily (NHL)Tirabrutinib 160 mg Once Daily (NHL)Tirabrutinib 320 mg Once Daily (NHL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 600 mg Once Daily (NHL)Tirabrutinib 240 mg Twice Daily (NHL)Total
< 65 years1031122100237762139
≥ 65 years23122112331211447251
Sex: Female, Male
Sex: Female, Male(Participants)Tirabrutinib 20 mg Once Daily (CLL)Tirabrutinib 40 mg Once Daily (CLL)Tirabrutinib 80 mg Once Daily (CLL)Tirabrutinib 160 mg Once Daily (CLL)Tirabrutinib 320 mg Once Daily (CLL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL)Tirabrutinib 300 mg Twice Daily (CLL)Tirabrutinib 20 mg Once Daily (NHL)Tirabrutinib 40 mg Once Daily (NHL)Tirabrutinib 80 mg Once Daily (NHL)Tirabrutinib 160 mg Once Daily (NHL)Tirabrutinib 320 mg Once Daily (NHL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 600 mg Once Daily (NHL)Tirabrutinib 240 mg Twice Daily (NHL)Total
Female0011100112101833225
Male33322332212571376165
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tirabrutinib 20 mg Once Daily (CLL)Tirabrutinib 40 mg Once Daily (CLL)Tirabrutinib 80 mg Once Daily (CLL)Tirabrutinib 160 mg Once Daily (CLL)Tirabrutinib 320 mg Once Daily (CLL)Tirabrutinib 400 mg Once Daily (CLL)Tirabrutinib 500 mg Once Daily (CLL)Tirabrutinib 600 mg Once Daily (CLL)Tirabrutinib 300 mg Twice Daily (CLL)Tirabrutinib 20 mg Once Daily (NHL)Tirabrutinib 40 mg Once Daily (NHL)Tirabrutinib 80 mg Once Daily (NHL)Tirabrutinib 160 mg Once Daily (NHL)Tirabrutinib 320 mg Once Daily (NHL)Tirabrutinib 480 mg Once Daily (NHL)Tirabrutinib 600 mg Once Daily (NHL)Tirabrutinib 240 mg Twice Daily (NHL)Total
White23413323233371698375
Asian000000000000010102
Other1002001010021410013
08

Study locations

6 sites
  • CHRU - Hopital Claude HURIEZ
    Lille, 59037, France
  • Centre hospitalier Lyon Sud
    Lyon, 69495, France
  • CHU St Eloi
    Montpellier, 34295, France
  • University Hospital of Wales
    Cardiff, CF14 4XW, United Kingdom
  • Leicester Royal Infirmary
    Leicester, LE1 5WW, United Kingdom
  • Derriford Hospital
    Plymouth, PL6 8DH, United Kingdom
09

References and documents

Publications

  • Walter HS, Salles GA, Dyer MJ. New Agents to Treat Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jun 2;374(22):2185-6. doi: 10.1056/NEJMc1602674. No abstract available. PubMed 27248633 ↗
  • Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV, Honda H, Duffy K, Birkett J, Jamieson V, Courtenay-Luck N, Yoshizawa T, Sharpe J, Ohno T, Abe S, Nishimura A, Cartron G, Morschhauser F, Fegan C, Salles G. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016 Jan 28;127(4):411-9. doi: 10.1182/blood-2015-08-664086. Epub 2015 Nov 5. PubMed 26542378 ↗
  • Fegan, C, Bagshawe J, Salles G, et al. The Bruton's tyrosine kinase (BTK) inhibitor ONO-4059: promising single agent activity and well tolerated in patients with high risk chronic lymphocytic leukaemia (CLL). Paper presented at: 56th American Society of Hematology Annual Meeting and Exposition; December 6-9, 2014; San Franscisco, CA.
  • Morschhauser F, Terriou L, Dyer M, et al. The Bruton's tyrosine kinase (BTK) inhibitor ONO-4059: promising single agent activity in patients with relapsed and refractory NHL. Haematologica. 2014 Jun; 99: 150.
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2012 to primary completion in Feb 2015, 30 months.

Results were first posted in Jan 2021, 5 years 11 months after primary completion.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's 30 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2012
First posted
Aug 7, 2012
StartActual
Aug 17, 2012
Primary completionActual
Feb 23, 2015
CompletionActual
Jan 11, 2016
Results first posted
Jan 28, 2021
Last update
Mar 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01659255
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 7, 2012
Start date
Aug 17, 2012
Primary completion
Feb 23, 2015
Completion
Jan 11, 2016
Results posted
Jan 28, 2021
Last update
Mar 16, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirabrutinib

Start the discussion